PMGC unit NorthStrive to launch independent FACS study to quantify EL-22 antigen expression

PMGC Holdings Inc.

PMGC Holdings Inc.

ELAB

0.00
  • PMGC Holdings unit NorthStrive Biosciences plans an independent flow-cytometry study to quantify EL-22 antigen expression on engineered Lactobacillus casei.
  • Program targets manufacturing comparability between NorthStrive-produced material and earlier EL-22 batches made by MOA Life Plus.
  • Work aims to tighten product identity controls, support manufacturing consistency, improve regulatory readiness for future IND-enabling development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief on July 09, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.